Biotest AG: Biotest donates human albumin for earthquake victims in Turkey

EQS-News: Biotest AG / Key word(s): Miscellaneous
Biotest AG: Biotest donates human albumin for earthquake victims in Turkey
14.03.2023 / 07:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Biotest donates human albumin for earthquake victims in Turkey

• Almost 2,000 severely affected victims can be supplied with human albumin
• Close interaction with Turkish Red Crescent (Kizilay) and the Turkish-German Health Foundation e.V. (Türk Alman Saglik Vakfi)

Dreieich, 14 March 2023. As a manufacturer of life-saving medicines, it was of great concern to Biotest AG from the very beginning to make a contribution to alleviating the need after the terrible earthquake disaster. This was a matter close to the hearts of our dedicated employees in particular. The best way for Biotest to help is to donate human albumin, one of our life-saving preparations to support intensive medical care. With this donation, around 2,000 severely injured victims can be cared for.

Thanks to the good relationship with our German partner, Turkish-German Health Foundation e.V. (Türk Alman Saglik Vakfi) and the local support provided by the Turkish Red Crescent (Kizilay) Albumin therapies will be distributed to emergency hospitals within the most vulnerable areas affected by the devastating earthquake.

Human albumin is used to treat or prevent shock following serious injury, bleeding, surgery, or burns by increasing the volume of blood plasma. Due to such considerations and given the high urgent medical need to treat tens of thousands of those injured, the delivery of this shipment is considered a high priority.

“Biotest's donation is a sign of our strong commitment to Turkish patients and more effective primary care for the most seriously injured”, says Enrico D’Aiuto, VP of Global Sales and Marketing at Biotest.

“Our thoughts are with the Turkish people in these very days, with the ones that lost their loved ones, with the ones that are struggling and fighting against the disastrous effects of this earthquake”, says Peter Janssen, Chief Operations Officer of Biotest AG.

About human albumin

Albumin is used in particular in intensive care medicine and acute care. Patients with extensive blood or fluid loss, due to burns among other things, have too little of the important proteins in their blood. This protein loss is compensated by administering Albumin. Albumin is also used for volume replacement in cases of blood poisoning. Unlike synthetically manufactured drugs, Albumin produced from human plasma offers particularly good tolerability. It is also the most important protein carrier in the blood for binding and removing (harmful) substances from the vascular system.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,200 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact

Dr Monika Buttkereit

Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Dirk Neumüller

Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201

Preference shares: securities’ ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

14.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com